| 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation X Zuo, L Shen, JP Issa, O Moy, JS Morris, SM Lippman, I Shureiqi The FASEB journal: official publication of the Federation of American …, 2008 | 33 | 2008 |
| 33 Cis-regulatory elements that promote CpG island demethylation J Si, Y Boumber, J Shu, J Jelinek, L Shen, JPJ Issa | | |
| 395 POSTER CpG island methylator phenotype (CIMP): a novel biomaker to predict new therapy for breast cancer Y Yu, W Feng, L Shen, DG Rosen, J Liu, Y Shen, KK Hunt, R Orlandi, ... EJC Supplements 12 (4), 121-122, 2006 | | 2006 |
| 5-azacytidine (5-AC), all-trans retinoic acid (ATRA), and valproic acid (VPA) in patients with acute myelogenous leukemia (AML): Molecular and clinical implications A Soriano, H Yang, S Verstovsek, W Wierda, C Koller, Z Estrov, ... Clinical Cancer Research 12 (19_Supplement), B48-B48, 2006 | | 2006 |
| 595 Improving specificity of epigenetic therapy through combined targeting of DNA and histone methylation T Sato, M Cesaroni, J Jelinek, JP Issa European Journal of Cancer, 192, 2014 | | 2014 |
| A Bayesian model for SNP discovery based on next-generation sequencing data Y Xu, X Zheng, Y Yuan, MR Estecio, JP Issa, Y Ji, S Liang Proceedings 2012 IEEE International Workshop on Genomic Signal Processing …, 2012 | 1 | 2012 |
| A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force S Beck, BE Bernstein, RM Campbell, JF Costello, D Dhanak, JR Ecker, ... Cancer research 72 (24), 6319-6324, 2012 | 32 | 2012 |
| A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome AD Kelly, H Kroeger, J Yamazaki, R Taby, F Neumann, S Yu, JT Lee, ... Cancer Research 76 (14_Supplement), 2779-2779, 2016 | 1 | 2016 |
| A DNMT3A-independent hypomethylator phenotype is a unifying epigenetic signature of AML with good risk cytogenetics AD Kelly, J Madzo, P Madireddi, P Kropf, CR Good, J Jelinek, JPJ Issa Cancer Research 77 (13_Supplement), 5382-5382, 2017 | | 2017 |
| A methylation center within intron 1 of RIL predisposes to silencing, and is opposed by a polymorphic Sp1/Sp3 site Y Boumber, M Estecio, C Tellez, S Ahmed, K Konishi, J Si, Y Kondo, ... Cancer Research 67 (9_Supplement), 2843-2843, 2007 | | 2007 |
| A microassay for measuring cytosine DNA methyltransferase activity during tumor progression SA Belinsky, KJ Nikula, SB Baylin, J Issa Toxicology letters 82, 335-340, 1995 | 15 | 1995 |
| A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer CR Good, J Madzo, B Patel, S Maegawa, N Engel, J Jelinek, JPJ Issa Nucleic Acids Research 45 (14), 8269-8281, 2017 | 68 | 2017 |
| A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer CR Good, J Madzo, S Maegawa, N Engel, J Jelinek, JP Issa Cancer Research 76 (14_Supplement), 2659-2659, 2016 | | 2016 |
| A parallel phase I/II clinical trial design for combination therapies X Huang, S Biswas, Y Oki, JP Issa, DA Berry Biometrics 63 (2), 429-436, 2007 | 137 | 2007 |
| A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome M Kirschbaum, I Gojo, SL Goldberg, C Bredeson, LA Kujawski, A Yang, ... British journal of haematology 167 (2), 185-193, 2014 | 136 | 2014 |
| A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: Impact on DNA methylation and lymphocyte populations ER Plimack, JR Desai, JP Issa, J Jelinek, P Sharma, LM Vence, ... Investigational new drugs 32, 969-975, 2014 | 14 | 2014 |
| A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer. MJ Overman, C Eng, BK Kee, DR Fogelman, RT Shroff, C Fark, ... Journal of Clinical Oncology 32 (3_suppl), 488-488, 2014 | 1 | 2014 |
| A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer. MJ Overman, C Eng, BK Kee, DR Fogelman, C Fark, R Hippert, S Holter, ... Journal of Clinical Oncology 30 (4_suppl), 450-450, 2012 | | 2012 |
| A phase I/II study of decitabine with pegylated interferon α-2b in advanced melanoma: clinical results and impact on DNA methylation and immune modulation ER Plimack, JP Issa, J Jelinek, P Sharma, L Vence, RL Bassett, JL Ilagan, ... Cancer Research 72 (8_Supplement), 5590-5590, 2012 | | 2012 |
| A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy. ER Plimack, K Campbell, JPJ Issa, NM Hahn, DI Quinn, HS Jang, ... CANCER RESEARCH 81 (13), 2021 | | 2021 |
